Skip to main content
Mar Riveiro-Barciela on Muck Rack

Mar Riveiro-Barciela

As seen in: Emerging Infectious Diseases, Wiley Online Library, MDPI, Texas Medical Center, Clinical Gastroenterology and Hepatology, JHEP Reports
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Mar

Contact Mar, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Unveiling Drug‐Induced Autoimmune‐Like Hepatitis in Autoimmune Hepatitis Patients: A Multicenter Retrospective Study

|
By Pinelopi Arvaniti, Mar Riveiro-Barciela, Ignasi Olivas, Ana Pascual-Dapena
| Wiley Online Library Verified
Opens in a new window Opens an external website Opens an external website in a new window To improve your experience, we (and our partners) store and/or access information on your terminal (cookie or equivalent) with your consent for all our websites and applications, on your connected terminals.
Open in Who Shared View Duplicates (684) Issue with article?

Expert Clinical Management of Severe Immune-Related Adverse Events: Results from a Multicenter Survey on Hot Topics for Management

|
By Mar Riveiro-Barciela, Maria Soler, Ana Barreira-Díaz, Sheila Bermejo
| Texas Medical Center
Keywords immune checkpoint inhibitors, immunotherapy, immune-related hepatitis, acute kidney injury, myositis, myocarditis Abstract There are differences in recommendations for the management of immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs). To assess the real-world management of irAEs, three surveys regarding ICI-induced hepatitis (IIH), renal irAEs, and myositis were developed and sent to experts in each area.
Open in Who Shared Issue with article?

Rituximab is a safe and effective alternative treatment for patients with autoimmune hepatitis: Results from the ColHai registry

|
By Mar Riveiro-Barciela, Ana Barreira-Díaz, Paula Esteban, Rosa Rota
| Wiley Online Library Verified
AEEH Association for the Study of the Liver AIH autoimmune hepatitis ALP alkaline phosphatase ALT alanine aminotransferase AMA anti-mitochondrial antibodies ANA antinuclear antibodies ANCA anti-neutrophil cytoplasmic antibody AST aspartate aminotransferase CBR complete biochemical response CMX trimethoprim-sulphamethoxazole CS corticosteroids HCC hepatocellular carcinoma IAIHG International AIH Group IgG immunoglobulin G IQR interquartile range MMF mycophenolate mofetil PBC primary biliary...
Open in Who Shared Issue with article?
See all 13 articles